{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T01:48:41Z","timestamp":1742953721094,"version":"3.40.3"},"publisher-location":"Cham","reference-count":37,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783031138690"},{"type":"electronic","value":"9783031138706"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-3-031-13870-6_58","type":"book-chapter","created":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T09:03:13Z","timestamp":1660467793000},"page":"701-725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Efficacy of Short-Term vs. Standard Periods Dual Antiplatelet Therapy After New-Generation Drug-Eluting Stent Implantation: A Meta-analysis"],"prefix":"10.1007","author":[{"given":"Xiaohua","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodan","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinpeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meili","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"issue":"jul21 1","key":"58_CR1","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati, A., Altman, D.G., Tetzlaff, J., et al.: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339(jul21 1), b2700\u2013b2700 (2009). https:\/\/doi.org\/10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"58_CR2","doi-asserted-by":"crossref","unstructured":"Cutlip, D.E., Windecker, S., Mehran, R., et al.: Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115(17), 2344\u20132351 (2007)","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"issue":"oct18 2","key":"58_CR3","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins, J.P.T., Altman, D.G., Gotzsche, P.C., et al.: The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343(oct18 2), d5928\u2013d5928 (2011). https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"issue":"7414","key":"58_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"J Higgins","year":"2003","unstructured":"Higgins, J., Thompson, S.G., Decks, J.J., et al.: Measuring inconsistency in meta-analyses. BMJ 327(7414), 557\u2013560 (2003)","journal-title":"BMJ"},{"issue":"9954","key":"58_CR5","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","volume":"384","author":"J Collet","year":"2014","unstructured":"Collet, J., Silvain, J., Barth\u00e9l\u00e9my, O., et al.: Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 384(9954), 1577\u20131585 (2014)","journal-title":"Lancet"},{"key":"58_CR6","unstructured":"Physicians, A., O'Gara, P.T., Kushner, F.G., et al.: ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J. Am. College Cardiol. 61(4), e78\u2013e140 (2013)"},{"key":"58_CR7","doi-asserted-by":"crossref","unstructured":"Whan, L.C., Jung-Min, A., Duk-Woo, P., et al.: Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation 129(3), 304\u2013312 (2014)","DOI":"10.1161\/CIRCULATIONAHA.113.003303"},{"key":"58_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3793","volume":"363","author":"E Kedhi","year":"2018","unstructured":"Kedhi, E., Fabris, E., van der Ent, M., et al.: Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ 363, k3793 (2018)","journal-title":"BMJ"},{"key":"58_CR9","doi-asserted-by":"crossref","unstructured":"Gwon, H.C., Hahn, J.Y., Park, K.W., et al.: Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 125(3), 505\u2013513 (2012)","DOI":"10.1161\/CIRCULATIONAHA.111.059022"},{"key":"58_CR10","doi-asserted-by":"crossref","unstructured":"Pascal, V., Marco, V., Peter, J., et al.: Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet (London, England) 392(10151), 940\u2013949 (2018)","DOI":"10.1016\/S0140-6736(18)31858-0"},{"issue":"2","key":"58_CR11","first-page":"B38","volume":"66","author":"Y Han","year":"2015","unstructured":"Han, Y., Xu, B., Xu, K., et al.: Six Versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 Trial. Circ. Cardiovasc. Interv. 66(2), B38\u2013B38 (2015)","journal-title":"Circ. Cardiovasc. Interv."},{"issue":"20","key":"58_CR12","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","volume":"36","author":"S Schulz-Schupke","year":"2015","unstructured":"Schulz-Schupke, S., Byrne, R.A., Berg, J.M., et al.: ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Euro. Heart J. 36(20), 1252\u20131263 (2015). https:\/\/doi.org\/10.1093\/eurheartj\/ehu523","journal-title":"Euro. Heart J."},{"key":"58_CR13","doi-asserted-by":"publisher","unstructured":"Hong, S.J., Shin, D.H., Kim, J.S., et al.: 6-month versus 12-month dual-antiplatelet therapy following\u00a0long\u00a0everolimus-eluting stent\u00a0implantation. JACC: Cardiovas. Intervent. 9(14), 1438\u20131446 (2016). https:\/\/doi.org\/10.1016\/j.jcin.2016.04.036","DOI":"10.1016\/j.jcin.2016.04.036"},{"issue":"23","key":"58_CR14","first-page":"2510","volume":"310","author":"F Feres","year":"2013","unstructured":"Feres, F., Costa, R.A., Abizaid, A., et al.: Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310(23), 2510\u20132522 (2013)","journal-title":"JAMA"},{"key":"58_CR15","doi-asserted-by":"crossref","unstructured":"Luca, G.D., Damen, S.A., Camaro, C., et al.: Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervent. J. EuroPCR Collabor. Work. Group Intervent. Cardiol. Euro. Soc. Cardiol. 15(11), e990\u2013e998 (2019)","DOI":"10.4244\/EIJ-D-19-00539"},{"key":"58_CR16","doi-asserted-by":"crossref","unstructured":"Byeong-Keuk, K., Myeong-Ki, H., Dong-Ho, S., et al.: A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J. Am. College Cardiol. 60(15), 1340\u20131348 (2012)","DOI":"10.1016\/S0735-1097(12)60008-4"},{"key":"58_CR17","doi-asserted-by":"crossref","unstructured":"Byoung-Kwon, L., Jung-Sun, K., Oh-Huyn, L., et al.: Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy. EuroIntervent. J. EuroPCR Collabor. Work. Group Intervent. Cardiol. Euro. Soc. Cardiol. 13(16), 1923\u20131930 (2018)","DOI":"10.4244\/EIJ-D-17-00792"},{"issue":"24","key":"58_CR18","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1001\/jama.2019.8146","volume":"321","author":"HJ Yong","year":"2019","unstructured":"Yong, H.J., Bin, S.Y., Hyeon, O.J., et al.: Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA 321(24), 2428\u20132437 (2019)","journal-title":"JAMA"},{"issue":"10127","key":"58_CR19","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","volume":"391","author":"J Hahn","year":"2018","unstructured":"Hahn, J., Song, Y.B., Oh, J., et al.: 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. The Lancet 391(10127), 1274\u20131284 (2018)","journal-title":"The Lancet"},{"issue":"24","key":"58_CR20","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.2019.8145","volume":"321","author":"W Hirotoshi","year":"2019","unstructured":"Hirotoshi, W., Takenori, D., Takeshi, M., et al.: Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 321(24), 2414\u20132427 (2019)","journal-title":"JAMA"},{"issue":"23","key":"58_CR21","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","volume":"323","author":"B Kim","year":"2020","unstructured":"Kim, B., Hong, S., Cho, Y., et al.: Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA 323(23), 2407\u20132416 (2020)","journal-title":"JAMA"},{"issue":"21","key":"58_CR22","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran, R., Baber, U., Sharma, S.K., et al.: Ticagrelor with or without aspirin in high-risk patients after PCI. N. Engl. J. Med. 381(21), 2032\u20132042 (2019)","journal-title":"N. Engl. J. Med."},{"key":"58_CR23","doi-asserted-by":"crossref","unstructured":"Colombo, A., Chieffo, A., Frasheri, A., et al.: Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J. Am. College Cardiol. 64(20), 2086\u20132097 (2014)","DOI":"10.1016\/j.jacc.2014.09.008"},{"issue":"1","key":"58_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","volume":"70","author":"GA Roth","year":"2017","unstructured":"Roth, G.A., Johnson, C., Abajobir, A., et al.: Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J. Am. Coll. Cardiol. 70(1), 1\u201325 (2017)","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10073","key":"58_CR25","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","volume":"389","author":"F Costa","year":"2017","unstructured":"Costa, F., Klaveren, D.V., James, S., et al.: Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389(10073), 1025\u20131034 (2017)","journal-title":"Lancet"},{"issue":"1","key":"58_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cjca.2017.10.004","volume":"34","author":"Y Arbel","year":"2018","unstructured":"Arbel, Y., Bennell, M.C., Goodman, S.G., et al.: Cost-effectiveness of different durations of dual-antiplatelet use after percutaneous coronary intervention. Can. J. Cardiol. 34(1), 31 (2018)","journal-title":"Can. J. Cardiol."},{"key":"58_CR27","doi-asserted-by":"crossref","unstructured":"Mehran, R., Baber, U., Steg, P.G., et al.: Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 382(9906), 1714\u20131722 (2013)","DOI":"10.1016\/S0140-6736(13)61720-1"},{"issue":"4","key":"58_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2005.09.060","volume":"47","author":"SV Rao","year":"2006","unstructured":"Rao, S.V., Grady, K.O., Pieper, K.S., et al.: A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J. Am. Coll. Cardiol. 47(4), 809\u2013816 (2006)","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"58_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/eurheartj\/ehn358","volume":"30","author":"A Budaj","year":"2008","unstructured":"Budaj, A., Eikelboom, J.W., Mehta, S.R., et al.: Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur. Heart J. 30(6), 655\u2013661 (2008)","journal-title":"Eur. Heart J."},{"issue":"9985","key":"58_CR30","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","volume":"385","author":"T Palmerini","year":"2015","unstructured":"Palmerini, T., Benedetto, U., Bacchi-Reggiani, L., et al.: Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 385(9985), 2371\u20132382 (2015)","journal-title":"Lancet"},{"key":"58_CR31","doi-asserted-by":"crossref","unstructured":"Bittl, J.A., Baber, U., Bradley, S.M., et al.: Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Associ. J. Am. College Cardiol. 2016, 1116\u20131139 (2016)","DOI":"10.1016\/j.jacc.2016.03.512"},{"key":"58_CR32","doi-asserted-by":"crossref","unstructured":"Mauri, L., Kereiakes, D.J., Yeh, R.W., et al.: Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. South China J. Cardiol. 371(4), 2155\u20132166 (2014)","DOI":"10.1056\/NEJMoa1409312"},{"key":"58_CR33","doi-asserted-by":"crossref","unstructured":"Dangas, G.D., Serruys, P.W., Kereiakes, D.J., et al.: Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. JACC: Cardiovasc. Intervent. 6(9), 914\u2013922 (2013)","DOI":"10.1016\/j.jcin.2013.05.005"},{"key":"58_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ijcard.2017.06.022","volume":"244","author":"G De Luca","year":"2017","unstructured":"De Luca, G., Smits, P., Hofma, S.H., et al.: Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Int. J. Cardiol. 244, 121\u2013127 (2017)","journal-title":"Int. J. Cardiol."},{"key":"58_CR35","first-page":"1034","volume":"14","author":"P Tullio","year":"2017","unstructured":"Tullio, P., Diego, D.R., Umberto, B., et al.: Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur. Heart J. 14, 1034\u20131043 (2017)","journal-title":"Eur. Heart J."},{"issue":"11","key":"58_CR36","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/clc.23075","volume":"41","author":"N Misumida","year":"2018","unstructured":"Misumida, N., Abo-Aly, M., Kim, S.M., et al.: Efficacy and safety of short-term dual antiplatelet therapy (\u22646 months) after percutaneous coronary intervention for acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin. Cardiol. 41(11), 1455\u20131462 (2018)","journal-title":"Clin. Cardiol."},{"key":"58_CR37","doi-asserted-by":"crossref","unstructured":"Mauri, L., Kereiakes, D.J., Yeh, R.W., et al.: Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. South China J. Cardiol 371, 2155\u20132166 (2014)","DOI":"10.1056\/NEJMoa1409312"}],"container-title":["Lecture Notes in Computer Science","Intelligent Computing Theories and Application"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-13870-6_58","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T17:01:17Z","timestamp":1709830877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-13870-6_58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783031138690","9783031138706"],"references-count":37,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-13870-6_58","relation":{},"ISSN":["0302-9743","1611-3349"],"issn-type":[{"type":"print","value":"0302-9743"},{"type":"electronic","value":"1611-3349"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"15 August 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"ICIC","order":1,"name":"conference_acronym","label":"Conference Acronym","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"International Conference on Intelligent Computing","order":2,"name":"conference_name","label":"Conference Name","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Xi'an","order":3,"name":"conference_city","label":"Conference City","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"China","order":4,"name":"conference_country","label":"Conference Country","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"2022","order":5,"name":"conference_year","label":"Conference Year","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"7 August 2022","order":7,"name":"conference_start_date","label":"Conference Start Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"11 August 2022","order":8,"name":"conference_end_date","label":"Conference End Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"18","order":9,"name":"conference_number","label":"Conference Number","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"icic2022","order":10,"name":"conference_id","label":"Conference ID","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"http:\/\/www.ic-icc.cn\/2022\/index.htm","order":11,"name":"conference_url","label":"Conference URL","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Open","order":1,"name":"type","label":"Type","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"IC-ICC-CN","order":2,"name":"conference_management_system","label":"Conference Management System","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"449","order":3,"name":"number_of_submissions_sent_for_review","label":"Number of Submissions Sent for Review","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"209","order":4,"name":"number_of_full_papers_accepted","label":"Number of Full Papers Accepted","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"0","order":5,"name":"number_of_short_papers_accepted","label":"Number of Short Papers Accepted","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"47% - The value is computed by the equation \"Number of Full Papers Accepted \/ Number of Submissions Sent for Review * 100\" and then rounded to a whole number.","order":6,"name":"acceptance_rate_of_full_papers","label":"Acceptance Rate of Full Papers","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"3","order":7,"name":"average_number_of_reviews_per_paper","label":"Average Number of Reviews per Paper","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"2.5","order":8,"name":"average_number_of_papers_per_reviewer","label":"Average Number of Papers per Reviewer","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"No","order":9,"name":"external_reviewers_involved","label":"External Reviewers Involved","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}}]}}